Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maiguan Fukang Tablets for Mild to Moderate Carotid Stenosis
ChiCTR2200057993Phase 4Not yet recruiting
- Sponsor
- Xiyuan Hospital of China Academy of Chinese Medical Sciences
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Maiguan Fukang in carotid atheroma (CAS) (2 arms), sponsored by Xiyuan Hospital of China Academy of Chinese Medical Sciences. Primary endpoint: Mean IMT of common carotid artery. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
Maiguan Fukang
03
Conditions
carotid atheroma (CAS)
Beyond the preview
Go deeper on ChiCTR2200057993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057993.